Received Feb 17, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | — | — |
original covid / rebound covid; original covid / rebound covid; This is a spontaneous report received from a Consumer or other non HCP. A patient (age and gender not provided) received BNT162b2 (BNT162B2 NOS), in Aug2024 as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Type 2 Diabetes", start date: May2023 (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (primary immunization series complete; unknown manufacturer), for COVID-19 immunization; Covid-19 vaccine (dose number unknown (booster); unknown manufacturer), for COVID-19 immunization. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "original covid / rebound covid". Therapeutic measures were taken as a result of vaccination failure, covid-19. Clinical course: Regularly get covid boosters when available. Last was Aug2024 before travel. Original covid symptoms included nasal congestion, some throat fever, aches, chills, minor cough, fatigue. The patient started treatment with oral Paxlovid from 23Jan2025 to 28Jan2025. Rebound symptoms included fatigue nasal congestion, shorter time sore throat, strong cough- no fever, aches or chills on never had any chest /lung issue. The patient is not allergic to any previous vaccination, medications, food or other products. The information on the batch/lot number for BNT162b2 will be requested and submitted if and when received.
Medical History/Concurrent Conditions: Type 2 diabetes mellitus